At 5x earnings and just 3.5x forward earnings, DXC is trading at deep-value multiples that imply either structural decline or elevated balance sheet risk. The valuation is optically cheap relative to EPS of 2.1 and estimated EPS of 2.36, but the Altman Z-Score of 1.1 signals real financial stress, not theoretical risk. A Price/Sales ratio of 0.2 and Price/Book of 0.6 suggest the market is discounting asset quality and durability of cash flows. This is not a clean growth story; it is a balance-sheet-constrained turnaround priced for skepticism, not optimism. The market is clearly embedding distress probability, and the low Forward P/E reflects survival risk rather than growth confidence.